Table I.
Patient demographics and baseline characteristics
| Baseline characteristics | OnabotulinumtoxinA (N = 735) |
|---|---|
| Male, n (%) | 394 (54) |
| Age at index date, mean (SD) | 60.7 (13.9) |
| Insurance type, n (%) | |
| Commercial | 479 (65.2) |
| Medicare | 256 (34.8) |
| Patients with stroke diagnosis prior to first onabotulinumtoxinA claima (index date), n (%) | 542 (73.7) |
| ≤ 180 days | 181 (33.4) |
| > 180 days | 361 (66.6) |
| ≤ 365 days | 420 (77.5) |
| > 365 days | 122 (22.5) |
| Charlson comorbidities within 12 months of index date, n (%) | |
| Cerebrovascular diseaseb | 735 (100) |
| Hemiplegiab | 694 (94.4) |
| Diabetes without chronic complication | 214 (29.1) |
| Peripheral vascular disease | 176 (23.9) |
| Chronic pulmonary disease | 139 (18.9) |
| Congestive heart failure | 128 (17.4) |
| Diabetes with chronic complication | 65 (8.8) |
| Any malignancy | 65 (8.8) |
| Renal disease | 61 (8.3) |
| Myocardial infarction | 60 (8.2) |
| Mild liver disease | 32 (4.4) |
| Dementia | 31 (4.2) |
| Peptic ulcer disease | 16 (2.2) |
| Rheumatic disease | 11 (1.5) |
| Metastatic solid tumour | 9 (1.2) |
| Moderate or severe liver disease | 3 (0.4) |
| AIDS/HIV | 1 (0.1) |
a
For the remainder of patients (26%), it was not possible to confirm stroke diagnosis based on medical history despite diagnosis of post-stroke spasticity and, therefore, they were omitted from sensitivity analysis.
b
These components of the Charlson Comorbidity Index were also represented among the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes for inclusion in this study.
SD: standard deviation.